Is Androgen Deprivation Therapy "Another Deficient Therapy" for Gleason Score 9-10 Prostate Cancer?

Matthew P Deek¹, Ryan M Phillips¹, Michael Haffner², Phuoc T Tran³

Affiliations

¹ Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
² Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA; The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
³ Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA; The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA; The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address: tranp@jhmi.edu.

PMID: 30268657
PMCID: PMC6330049
DOI: 10.1016/j.eururo.2018.09.027

Editorial

Is Androgen Deprivation Therapy "Another Deficient Therapy" for Gleason Score 9-10 Prostate Cancer?

Matthew P Deek et al. Eur Urol. 2019 Jan.

. 2019 Jan;75(1):42-43.

doi: 10.1016/j.eururo.2018.09.027. Epub 2018 Sep 26.

Authors

Matthew P Deek¹, Ryan M Phillips¹, Michael Haffner², Phuoc T Tran³

Affiliations

¹ Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
² Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA; The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
³ Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA; The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA; The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address: tranp@jhmi.edu.

PMID: 30268657
PMCID: PMC6330049
DOI: 10.1016/j.eururo.2018.09.027

No abstract available

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST

PTT co-owns the patent “Compounds and Methods of Use in Ablative Radiotherapy” (patent#: 9114158). PTT receives institutional research support from Medivation Inc-Astellas Pharma and and RefleXion Medical and has consulted for RefleXion Medical.

Comment on

Androgen Deprivation Therapy and Overall Survival for Gleason 8 Versus Gleason 9-10 Prostate Cancer.
Yang DD, Mahal BA, Muralidhar V, Martin NE, Orio PF, Mouw KW, King MT, Choueiri TK, Trinh QD, Hoffman KE, Spratt DE, Feng FY, Nguyen PL. Yang DD, et al. Eur Urol. 2019 Jan;75(1):35-41. doi: 10.1016/j.eururo.2018.08.033. Epub 2018 Oct 24. Eur Urol. 2019. PMID: 30554605

References

1. Yang DD, et al., Androgen Deprivation Therapy and Overall Survival for Gleason 8 Versus Gleason 9–10 Prostate Cancer. Eur Urol, (in press). - PubMed
1. D’Amico AV, Is Gleason Grade 5 Prostate Cancer Resistant to Conventional Androgen Deprivation Therapy? Eur Urol, 2016. 69(5): p. 761–3. - PubMed
1. Huynh MA, et al., Gleason Score 3 + 5 or 5 + 3 versus 4 + 4 Prostate Cancer: The Risk of Death. Eur Urol, 2016. 69(6): p. 976–9. - PubMed
1. Narang AK, et al., Very High-Risk Localized Prostate Cancer: Outcomes Following Definitive Radiation. Int J Radiat Oncol Biol Phys, 2016. 94(2): p. 254–62. - PMC - PubMed
1. Epstein JI, et al., A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score. Eur Urol, 2016. 69(3): p. 428–35. - PMC - PubMed

Publication types

Actions
Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Is Androgen Deprivation Therapy "Another Deficient Therapy" for Gleason Score 9-10 Prostate Cancer?

Affiliations

Is Androgen Deprivation Therapy "Another Deficient Therapy" for Gleason Score 9-10 Prostate Cancer?

Authors

Affiliations

Conflict of interest statement

Comment on

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Medical